Skip to content
thestock.space

Anlon Healthcare (AHCL) had a P/E of 50.9× on 6 Nov 2026, above the industry P/E of 28.7×, and the shares are 27% below their 52-week high. It earns ROCE of 17% and ROE of 16%, and sales and net profit grew 15% and 70% a year over 3 years. Debt is 0.24× equity. It is a small-cap company with a market cap of ₹1,435 Cr, ranked 64th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 101% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹28.30
Day high
₹28.40
Day low
₹26.75
Prev. close
₹27.99
Volume
44.7 L

Health check

2 good · 2 fair · 2 to check
  • ReturnsAhead

    +101.0% over a year, better than 6 of 7 peers.

  • Price tagPricier

    P/E 50.9 vs industry 28.7.

  • GrowthStrong

    Sales +15.1%, profit +69.8% a year over 3 years.

  • ProfitabilityAverage

    ROCE 17.0% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.24× equity, interest covered 16.5×, Piotroski 5 of 9.

  • Red flags1 to check

    P/E of 50.9 against an industry P/E of 28.7.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹1,435 Cr, #64 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹280 Cr · profit ₹36 Cr
Market cap
₹1,435 Cr
Small cap
P/E
50.9
Industry 28.7
Price to book
4.38
Peers 4.99
Dividend yield
0.00%
ROE
16.4%
Peers 14.7%
ROCE
17.0%
Peers 17.9%
Debt to equity
0.24
Debt ₹72 Cr
EPS (TTM)
₹0.53
Face value ₹2
OPM (TTM)
24.5%
Net margin 12.8%
Sales growth
+102.3%
Latest quarter vs a year ago
Profit growth
+43.5%
Latest quarter vs a year ago
Price to sales
5.13
EV/EBITDA 17.9

Strengths and risks

Strengths

  • Quarterly profit up 43.5% on a year ago.
  • Quarterly sales up 102.3% on a year ago.

Risks to check

  • P/E of 50.9 against an industry P/E of 28.7.

Derived automatically from reported figures. Not a recommendation.

About Anlon Healthcare

Anlon Healthcare Limited manufactures and sells active pharmaceutical ingredients in India and internationally. The company also offers bulk drugs; advanced pharmaceutical intermediates; nutraceutical API products; and drug intermediates. It also manufactures loxoprofen sodium dihydrate, ketoprofen, and dexketoprofen trometamol products for pain management and anti-inflammatory therapies. Anlon Healthcare Limited was incorporated in 2013 and is based in…

Headquarters
Rajkot
Employees
119
Sector
Healthcare
ISIN
INE0Y8W01025
Website
anlon.in

Price range

52 weeks

₹10.37₹37.24

Today

₹26.75₹28.40
Avg volume (3M)
2.2 Cr
1-year return
plus 101.0%
From 52-week high
minus 27.5%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
AHCLAnlon Healthcare27.00minus 3.54%1,43550.94.3817.0%16.4%25.2%15.1%69.8%0.00%plus 101.0%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrSep 25Dec 25Mar 26Jun 26Sep 26
52.235.650.987.6106
38.523.235.67280.4
13.712.315.315.625.2
26.3%34.7%30.0%17.8%23.9%
00.21,4300.10
0.81.60.60.90.9
0.50.40.31.11
12.410.61,44413.723.5
25.1%51.5%−0.2%39.4%26.8%
9.35.210.56.713.4
0.180.110.230.160.32

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+15.1%
Profit CAGR 3Y
+69.8%
EPS CAGR 3Y
+76.2%
ROE
16.4%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
11366.6120172
–minus 41.0%+80.7%+43.0%
10050.987.9124
12.915.732.347.8
11.5%23.6%26.9%27.8%
−0.3−0−0.2−1
3.84.13.42.7
1.91.91.81.5
––−0–
79.826.942.5
16.8%1.0%23.7%31.6%
5.89.720.528.5
–+65.9%+112.5%+39.0%
0.110.180.390.60

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
121639.953.2
−4.6540.6177
70.381.266.643.7
33.925.734.3100
112128181374
25.727.322.846.8
–––6.6
–––1
4.53.12.44.4
81.397.6156315
112128181374

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
−2.8−3.2−22.6−79.4
−0.3−3.42.8−36.3
2.38.218.9119
−0.91.7−0.82.9
−0.4−3.5−0.5−36.5
−3.2−6.8−23.1−116

Shareholding pattern

Source: NSE filings
52.7%
promoters
  • Promoters52.68%
  • Public47.32%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202652.68%47.32%0.00
30 Jun 202652.68%47.32%0.00
31 Mar 202652.68%47.32%0.00
31 Dec 202552.68%47.32%0.00
30 Sep 202552.68%47.32%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you